A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-03-06) →
What happened
Onconic Therapeutics reported separate results for FY2025: revenue of US$36.9M (+259.8% year on year), operating profit of US$8.71M (from a loss a year earlier) and net income of US$9.47M (from a loss a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$36.9M |
|---|---|
| Revenue vs a year earlier | +259.8% |
| Operating profit | US$8.71M |
| Net income | US$9.47M |
| Period | FY2025 (separate) |
| Filed | 2026-02-02, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260202900365 → open original filing |
Versions of this filing
- 2026-02-02Original (this page)
- 2026-03-06Amendment 1
- 2026-03-06Amendment 2
Source: DART. Information only, not investment advice.